No Data
Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma
Merck, J&J, Bristol Decline on Proposed CMS Drug Price Rule
J&J, Bristol-Myers Face Negotiation Risk Under New CMS Rule, Says RBC Capital
Process Industries Converge in Houston for Inaugural ChemE Show 2026 Powered by ACHEMA
Johnson & Johnson (JNJ) Boosts Vision Operations in $55B U.S. Manufacturing Push
Express News | J&J - New Facility Targeted to Be Fully Operational in 2028